13504-15-9 Usage
Description
17,21-Dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione, also known as Methylprednisolone, is a synthetic corticosteroid hormone that exhibits potent anti-inflammatory and immunosuppressive properties. Derived from the chemical modification of natural corticosteroids, Methylprednisolone effectively reduces inflammation and modulates the immune system by inhibiting the release of pro-inflammatory mediators and altering immune responses. This versatile medication is widely prescribed for a range of conditions, including allergic reactions, skin disorders, arthritis, respiratory issues, and certain cancers, demonstrating its efficacy in various therapeutic applications.
Uses
Used in Pharmaceutical Industry:
17,21-Dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is used as an anti-inflammatory and immunosuppressive agent for the treatment of various conditions characterized by excessive inflammation or immune system overactivity. Its application in this industry is primarily due to its ability to suppress the immune response and reduce inflammation, providing relief to patients suffering from a wide array of disorders.
Used in Allergy Treatment:
In the field of allergy treatment, 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is utilized as a medication to alleviate symptoms associated with allergic reactions. Its anti-inflammatory and immunosuppressive properties help in reducing the severity and frequency of allergic responses, offering relief to patients with conditions such as asthma, rhinitis, and dermatitis.
Used in Dermatology:
17,21-Dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is employed as a therapeutic agent in dermatology for the management of various skin conditions. Its potent anti-inflammatory effects make it suitable for treating skin disorders such as eczema, psoriasis, and contact dermatitis, promoting skin healing and reducing inflammation.
Used in Rheumatology:
In rheumatology, 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is used as a medication to treat inflammatory joint diseases, such as rheumatoid arthritis and lupus. Its ability to suppress the immune system and reduce inflammation helps in managing pain, swelling, and joint damage associated with these conditions.
Used in Respiratory Medicine:
17,21-Dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is utilized in respiratory medicine for the treatment of breathing problems, including severe asthma and chronic obstructive pulmonary disease (COPD). Its anti-inflammatory properties help in reducing airway inflammation and improving lung function in patients with these respiratory disorders.
Used in Oncology:
In the field of oncology, 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione is used as a medication to manage certain types of cancer, particularly those that are sensitive to corticosteroid therapy. Its immunosuppressive effects can help in controlling the growth and spread of cancer cells, as well as alleviating symptoms associated with cancer and its treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 13504-15-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,5,0 and 4 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13504-15:
(7*1)+(6*3)+(5*5)+(4*0)+(3*4)+(2*1)+(1*5)=69
69 % 10 = 9
So 13504-15-9 is a valid CAS Registry Number.
13504-15-9Relevant articles and documents
Non-hormonal steroid modulators of NF-κβ for treatment of disease
-
Page/Page column 42-43; 44, (2019/11/18)
The present invention relates to compounds and methods which may be useful as treatments of diseases.
NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE
-
Paragraph 0208, (2013/06/27)
The present invention relates to compounds and methods which may be useful as treatments of diseases.
Catalytic Epoxidation of Alkenes with Oxone
Denmark, Scott E.,Forbes, David C.,Hays, David S.,DePue, Jeffrey S.,Wilde, Richard G.
, p. 1391 - 1407 (2007/10/02)
A practical, general and efficient protocol for the catalytic epoxidation of alkenes has been developed.The in situ generation of reactive dioxiranes capable of epoxidizing a variety of alkenes under biphasic conditions has been accomplished using phase transfer catalysts bearing a carbonyl group.Optimal epoxidation conditions employ 10 mol percent of 1-dodecyl-1-methyl-4-oxopiperidinium triflate (8d(+)OTf(-)) in a CH2Cl2/pH 7.5-8.0 biphase using potassium monoperoxosulfate (Oxone) as the oxidant.Optimization of the conditions identified (1) slow addition rate, (2) pH 7.5-8.0, (3) N-dodecyl chain, and (4) the triflate salt as key experimental and structural variables.A selection of nine olefins was successfully oxidized to the corresponding epoxides in 83-96percent yield.
